ITMAT External Advisory Board
Barry Coller, MD (Committee Co-Chair)
Professor | Physician-in-Chief, Vice President for Medical Affairs | The Rockefeller University
Barry S. Coller, M.D., is Vice President for Medical Affairs at The Rockefeller University and physician-in-chief of its hospital. A renowned physician, researcher and medical educator, Dr. Coller is an expert on the basic molecular mechanisms involved in blood clotting and thrombosis. His research accomplishments include the development of a monoclonal antibody to platelets that was developed into the drug abciximab, which is used throughout the world to prevent and treat heart attacks in select patient populations.
Pamela B. Davis, MD, PhD (Co-PI)
Dean | School of Medicine | Senior Vice President for Medical Affairs | Case Western Reserve University
A renowned physician and medical researcher, Pamela B. Davis, MD, PhD, received her AB summa cum laude from Smith College and her MD and PhD from Duke. Following internship and residency at Duke Hospital, she trained at the National Institutes of Health in pulmonary medicine and cystic fibrosis research. She became dean of the School of Medicine in 2007 and she is senior vice president for medical affairs at Case Western Reserve University. She currently holds the Arline H. and Curtis F. Garvin Research Professorship. She previously served as chief of the pediatric pulmonary division at Rainbow Babies and Childrens' Hospital and as director of the Willard A. Bernbaum Cystic Fibrosis Research Center at Case Western Reserve University.
Additionally, Dean Davis holds seven U.S. patents and is a founding scientist of Copernicus Therapeutics Inc., a biotechnology company that creates novel pharmaceutical targeting and delivery systems. She was the principal investigator for the school’s $64.6 million Clinical and Translational Award program and was elected as the 2015 Chair of the Medical Sciences Section of the American Association for the Advancement of Science. She has published more than 130 articles in peer-reviewed journals and has served in prominent roles such as the Advisory Council to the National Institute of Diabetes and Digestive and Kidney Diseases, the Board of Scientific Counselors for the National Heart, Lung and Blood Institute and the Advisory Council for National Center for Advancing Translational Sciences.
In 2014, Dean Davis, whose work focuses largely on cystic fibrosis, was inducted into the Institute of Medicine, now known as the National Academy of Medicine. Among many other honors, she has been a recipient of the Paul Di Sant’Agnese Award from the Cystic Fibrosis Foundation, the Rosenthal Prize for academic pediatrics, the Smith College Medal, and has regularly been named in "Best Doctors in America" and "Top Doctors." In 2014, Dean Davis was locally recognized as a Crain’s Cleveland Business “Woman of Note.” She also has been elected to the Association of American Physicians and inducted into both the Cleveland Medical Hall of Fame and the Ohio Women’s Hall of Fame.
As dean of one of the top medical schools in the nation, Dean Davis is committed to three main goals: (1) excellence in medical education, based on the innovative Western Reserve2 curriculum and the curriculum of the Cleveland Clinic Lerner College of Medicine, a track within the school’s education program; (2) advancing discoveries from our laboratories to the patients; and (3) improving the health of our community.
Sir Gordon Duff, MD, PhD, FRCP, FMedSci, FRSE
Chairman | MHRA | Principal | St. Hilda's College of Oxford
Gordon is Chairman of the MHRA, the UK regulator of medicines and devices, having previously chaired the Commission on Human Medicines (CHM). He was co-chair of the Cabinet Office's Scientific Advisory Group for Emergencies (SAGE) and the UK Scientific Pandemic Influenza Committee. In 2006, he led the investigation into the disastrous clinical trial of TGN1412, providing safety recommendations for first human exposure to innovative medicines. He was Lord Florey Professor of Molecular Medicine at University of Sheffield (1990-2013), Director of the Division of Genomic Medicine, and Faculty Research Dean. His research interests are in cytokine biology and medicine. He also currently chairs Imperial College's Academic Health Science Centre, and the Academic Health Science Centre of Trinity College, Dublin. In August 2014 he became Principal of St Hilda's College, Oxford. He was knighted in 2007 for services to the public health.
Desmond Fitzgerald, MD
President-elect | University of Limerick | UCD Vice-President for Health Affairs
Professor Desmond Fitzgerald is Professor of Molecular Medicine and UCD Vice-President for Health Affairs. He is a UCD medical graduate who trained in Cardiology and Clinical Pharmacology at Vanderbilt University. He remained in the US until 1991 as Associate Professor of Medicine and Pharmacology and Director of the VA Coronary Care Unit. From 1994, he was Professor of Clinical Pharmacology and later Head of Research at RCSI. From 2004, he held various positions in UCD including Vice-President for Research. He has served on several national bodies, including the Irish Medicines Board, the Health Research Board (which he chaired) and the Irish Heart Foundation, as well as committees of the European Society of Cardiology, the UK National Institute for Health Research and the Merck Foundation International Fellowship Programme. He has published on cardiovascular disease, thrombosis, genetics and proteomics. He is President-elect of the University of Limerick and will take up his appointment in May 2017.
In Seon Hwang, MBA
Managing Director | Warburg Pincus LLC
In Seon Hwang is based in New York, joined Warburg Pincus in 2004 and leads the firm's investment activities in healthcare, consumer and retail sectors. Mr. Hwang is also a member of the firm's executive management group. Previously, he worked at GSC Partners, Goldman Sachs and the Boston Consulting Group. He is an investment committee member of Sheridan Production Partners and serves on the board of Hope for New York. Mr. Hwang received a B.S. in economics from The Wharton School of the University of Pennsylvania and an M.B.A. from Harvard Business School.
Isaac Kohane, MD, PhD
Lawrence J. Henderson Professor of Pediatrics | Harvard Medical School
Isaac Kohane, MD, PhD, co-directs the Center for Biomedical Informatics at Harvard Medical School. He applies computational techniques, whole genome analysis, and functional genomics to study human diseases through the developmental lens, and particularly through the use of animal model systems. Kohane has led the use of whole healthcare systems, notably in the i2b2 project, as "living laboratories" to drive discovery research in disease genomics (with a focus on autism) and pharmacovigilance (including providing evidence for the cardiovascular risk of hypoglycemic agents which ultimately contributed to "black box"ing by the FDA) and comparative effectiveness with software and methods adopted in over 84 academic health centers in the internationally.
Dr. Kohane has published over 200 papers in the medical literature and authored a widely used book on Microarrays for an Integrative Genomics. He has been elected to multiple honor societies including the American Society for Clinical Investigation, the American College of Medical Informatics, and the Institute of Medicine. He leads a doctoral program in genomics and bioinformatics within the Division of Medical Science at Harvard University. He is also an occasionally practicing pediatric endocrinologist.
Calum MacRae, MD, PhD
Chief, Cardiovascular Medicine | Brigham and Women's Hospital | Associate Professor of Medicine | Harvard Medical School
Calum MacRae MD, PhD is Chief of Cardiovascular Medicine at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School. He is also an Associate Member at the Broad Institute and a Principal Faculty Member at the Harvard Stem Cell Institute. His research is focused on understanding the developmental mechanisms of disease through human genetics and high-throughput genetic or chemical screens in the zebrafish. His clinical interests include genomic medicine, innovation in phenotyping and the redesign of clinical care.
Steven Nichtberger, MD
Adjunct Professor of Health Management | The Wharton School, University of Pennsylvania
Dr. Nichtberger is a serial entrepreneur with 25 years of healthcare experience focused on developing and commercializing breakthrough medical advances. In addition to leading the capstone course for the Vagelos Life Sciences & Management program at Penn where students form real companies around promising scientific advances while learning about leadership, he has recently focused his investment and company formation efforts on healthcare advances derived from Israeli technologies. He is currently chairman of the board of two recently formed companies. He provides advisory services to investors, biotech companies, and leading academic scientists to maximize the value of breakthrough advances. Previously, Dr. Nichtberger was the head of global marketing for the company at Merck, where he co-chaired the clinical research resource allocation committee. In 2008, he was awarded the prestigious Ernst & Young National Entrepreneur of the Year award for his leadership of a regenerative medicine company. In 1984, Dr. Nichtberger founded the first paperless coupon company, which subsequently licensed core intellectual property to numerous internet coupon providers until 2006. He is a longstanding member of the SAS board of overseers at Penn, past chairman of the board of PA Bio, and a member of the board of governors at Main Line Health.
Sir Keith Peters, FRCP, FRS, FMedSCi
Senior Consultant to the President of Pharmaceuticals R&D | GlaxoSmithKline
Sir Keith’s research has been on elucidation of immunological mechanisms underlying diseases of kidney and blood vessels, this has led to new treatments of these diseases. Cambridge, under Sir Keith’s leadership, has become a major centre for clinical research, complementing the University’s longstanding strengths in basic biomedical science. He was a founder Fellow of the Academy of Medical Sciences and its second President. From 2006-2008 Sir Keith was Interim Director of the MRC’s National Institute for Medical Research and initiated discussions which led to the establishment of the UK Centre for Medical Research and Innovation, the Francis Crick Institute. The Institute – at St Pancras - is a partnership between the MRC, CRUK. The Wellcome Trust, and UCL, KCL and Imperial College. Sir Keith is currently acting as a consultant in Clinical Science and Translational Medicine for the Institute. For the past 10 years he has been a Senior Consultant to the President of Pharmaceuticals R&D at GlaxoSmithKline and has served on the science advisory boards of various biotechnology companies including Cambridge Antibody Technology.